Prevalence of Candida auris in Canadian acute care hospitals among at-risk patients, 2018
Hector Felipe Garcia-Jeldes, Robyn Mitchell, Allison McGeer, Wallis Rudnick, Kanchana Amaratunga, Snigdha Vallabhaneni, Shawn R. Lockhart, CNISP C. auris Interest Group, Ghada N. Al‐Rawahi, Elizabeth Brodkin, Marthe Charles, Jeannette Comeau, Ian Davis, Johan Delport, Tanis C. Dingle, Philippe J. Dufresne, Chelsey Ellis, Joanne Embreé, Charles Frenette, George R. Golding, Linda Hoang, Susy Hota, Kevin Katz, Pamela Kibsey, Julianne V. Kus, Joanne M. Langley, Bonita E. Lee, Marie-Astrid Lefebvre, Yves Longtin, Kathy Malejczyk, Shazia Masud, Dominik Mertz, Michael R. Mulvey, Susan M. Poutanen, Dale Purych, Rajni Rantelidis, David Richardson, Ilan S. Schwartz, Stephanie Smith, Maxime-Antoine Tremblay, Titus Wong, Deborah Yamamura, Amrita Bharat
Abstract
To identify the prevalence of C. auris in Canadian patients who are potentially at risk for colonization, we screened 488 patients who were either hospitalized abroad, had a carbapenemase-producing organism (CPO), or were in units with high antifungal use. Two patients were colonized with C. auris; both had received healthcare in India and had a CPO. Among 35 patients who had recently received healthcare in the Indian subcontinent and were CPO colonized or infected, the prevalence of C. auris was 5.7%.